Biofrontera AG (B8F):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Biofrontera AG (B8F) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9845
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Biofrontera AG (Biofrontera) is a biopharmaceutical company that develops and commercializes dermatological medications and medical cosmetics. The company’s products comprise Ameluz, BF-RhodoLED and Belixos. Its prescription drug Ameluz is used for the treatment of skin disease actinic keratosis. Biofrontera’s BF-RhodoLED is a lamp used for photodynamic therapy with LEDs emitting red light. Belixos is a cosmetic product,indicated for regenerative care of reddened and inflamed skin. Its Belixos line of products include Belixos creme, Belixos liquid, Belixos gel, Belixos to go and Belixos protect. The company sells products to wholesalers, physicians, clinics and licensing partners. Biofrontera is headquartered in Leverkusen, Germany.

Biofrontera AG (B8F) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biofrontera AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biofrontera AG, Medical Devices Deals, 2012 to YTD 2018 10
Biofrontera AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Biofrontera AG, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Deutsche Balaton to Acquire 14% Stake in Biofrontera 12
Partnerships 13
Biofrontera Extends Its Agreement with Maruho 13
Biofrontera Enters Into Co-Marketing Agreement With Desitin For Ameluz 14
Licensing Agreements 15
Biofrontera Pharma Enters into Licensing Agreement with Louis Widmer 15
Biofrontera Enters Into Licensing Agreement With Pharma.MT For Ameluz 16
Equity Offering 17
Biofrontera Raises USD13 Million in Public Offering of ADS 17
Biofrontera Raises USD17 Million in Rights Offering of Shares 19
Biofrontera Secures USD22.2 Million in Financing 20
Biofrontera to Raise USD16.5 Million in Private Placement of Shares 21
Biofrontera Raises USD5 Million in Private Placement of Shares 22
Biofrontera Raises USD4 Million in Rights Offering of Shares 23
Biofrontera to Raise up to USD3.4 Million in Private Placement of Shares 24
Biofrontera Raises USD3.4 Million in Rights Offering of Shares 25
Biofrontera Completes Private Placement Of Shares For US$9.7 Million 26
Biofrontera Completes Rights Offering Of Shares For US$15 Million 27
Debt Offering 28
Biofrontera Raises USD5.5 Million in Private Placement of Debentures 28
Biofrontera Raises USD5.5 Million in Private Placement of Bonds Due 2020 29
Acquisition 30
Carsten Maschmeyer Acquires Additional 15.1% Stake In Biofrontera 30
Biofrontera AG – Key Competitors 31
Biofrontera AG – Key Employees 32
Biofrontera AG – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Oct 10, 2018: Biofrontera announces preliminary unaudited sales revenue for the first nine months of 2018 and increases revenue guidance 34
Sep 17, 2018: Biofrontera uses the long summer months to introduce daylight photodynamic therapy (PDT) with Ameluz in the EU 35
Aug 31, 2018: Biofrontera reports significant revenue growth for the first 6 months of 2018 36
Jul 05, 2018: Biofrontera: Sales revenue for Ameluz(R) doubled for the six-month period ended June 30, 2018 38
May 30, 2018: Biofrontera Announces First Quarter 2018 Financial Results 39
Apr 30, 2018: Biofrontera Announces Full Year 2017 Financial Results 41
Apr 12, 2018: Biofrontera announces preliminary unaudited sales revenues for the 1st Quarter 2018 44
Jan 22, 2018: Biofrontera Announces Preliminary Unaudited Full Year 2017 Revenue 45
Nov 27, 2017: Biofrontera Reports Financial Results for Third Quarter and First Nine Months of 2017 46
Nov 14, 2017: Biofrontera adjusts revenues and earnings forecast for the financial year 2017 48
Aug 31, 2017: Biofrontera Grows Revenues and Improves Financial Position in First Half 2017 49
Legal and Regulatory 51
Jul 12, 2018: Biofrontera: Biofrontera subsidiary files suit against DUSA Pharmaceuticals 51
Jul 11, 2018: DUSA pharmaceuticals files patent infringement suit against German drug maker Biofrontera 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Biofrontera AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biofrontera AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biofrontera AG, Deals By Therapy Area, 2012 to YTD 2018 9
Biofrontera AG, Medical Devices Deals, 2012 to YTD 2018 10
Biofrontera AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Deutsche Balaton to Acquire 14% Stake in Biofrontera 12
Biofrontera Extends Its Agreement with Maruho 13
Biofrontera Enters Into Co-Marketing Agreement With Desitin For Ameluz 14
Biofrontera Pharma Enters into Licensing Agreement with Louis Widmer 15
Biofrontera Enters Into Licensing Agreement With Pharma.MT For Ameluz 16
Biofrontera Raises USD13 Million in Public Offering of ADS 17
Biofrontera Raises USD17 Million in Rights Offering of Shares 19
Biofrontera Secures USD22.2 Million in Financing 20
Biofrontera to Raise USD16.5 Million in Private Placement of Shares 21
Biofrontera Raises USD5 Million in Private Placement of Shares 22
Biofrontera Raises USD4 Million in Rights Offering of Shares 23
Biofrontera to Raise up to USD3.4 Million in Private Placement of Shares 24
Biofrontera Raises USD3.4 Million in Rights Offering of Shares 25
Biofrontera Completes Private Placement Of Shares For US$9.7 Million 26
Biofrontera Completes Rights Offering Of Shares For US$15 Million 27
Biofrontera Raises USD5.5 Million in Private Placement of Debentures 28
Biofrontera Raises USD5.5 Million in Private Placement of Bonds Due 2020 29
Carsten Maschmeyer Acquires Additional 15.1% Stake In Biofrontera 30
Biofrontera AG, Key Competitors 31
Biofrontera AG, Key Employees 32
Biofrontera AG, Subsidiaries 33

List of Figures
Biofrontera AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biofrontera AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biofrontera AG, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Biofrontera AG (B8F):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Neptune Marine Services Ltd (NMS):企業の財務・戦略的SWOT分析
    Summary Neptune Marine Services Ltd (NMSL), a subsidiary of MTQ Corp Ltd, is an engineering solutions provider. The company's services include commercial diving; manufacturing, testing and assembly; dry underwater welding; survey, geophysical and geotechnical services, asset integrity services, ROV …
  • PT Tigaraksa Satria Tbk (TGKA):企業の財務・戦略的SWOT分析
    PT Tigaraksa Satria Tbk (TGKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Central Electricity Generating Co:企業の戦略的SWOT分析
    Central Electricity Generating Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Modus Therapeutics Holding AB-製薬・医療分野:企業M&A・提携分析
    Summary Modus Therapeutics Holding AB (Modus), formerly known as Dilaforette Holding AB, is a biotechnology company that focuses on the development of sevuparin, a proprietary polysaccharide drug for the treatment of sickle cell disease (SCD). Modus Therapeutics Holding AB - Pharmaceuticals & Health …
  • Porcelanosa Grupo AIE:企業の戦略・SWOT・財務情報
    Porcelanosa Grupo AIE - Strategy, SWOT and Corporate Finance Report Summary Porcelanosa Grupo AIE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • PetroNeft Resources plc (P8ET):石油・ガス:M&Aディール及び事業提携情報
    Summary PetroNeft Resources Plc (PetroNeft) is an upstream oil and gas company. It carries out exploration, development and production of oil and natural gas. The company mainly focuses on oil rich Western Siberia zone in Russia. PetroNeft’s asset base comprises of 50% interest each in License 61 an …
  • Ana Holdings Inc.:戦略・SWOT・企業財務分析
    Ana Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Ana Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Humanwell Healthcare (Group) Co Ltd (600079):医療機器:M&Aディール及び事業提携情報
    Summary Humanwell Healthcare (Group) Co Ltd (Humanwell), formerly Wuhan Humanwell Hi-Tech Industry Co Ltd is a pharmaceutical company that offers generic products. The company offers pharmaceutical, medical instrument and reproductive health care products and technologies. Its products include anest …
  • Investimentos, Participacoes e Gestao SA (INA):企業の財務・戦略的SWOT分析
    Investimentos, Participacoes e Gestao SA (INA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Gooderson Leisure Corporation Limited:企業の戦略・SWOT・財務情報
    Gooderson Leisure Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Gooderson Leisure Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • National Rural Utilities Cooperative Finance Corporation:企業の戦略・SWOT・財務情報
    National Rural Utilities Cooperative Finance Corporation - Strategy, SWOT and Corporate Finance Report Summary National Rural Utilities Cooperative Finance Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the comp …
  • Haitong Securities Co., Ltd.:企業の戦略・SWOT・財務分析
    Haitong Securities Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Haitong Securities Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • PTT Exploration and Production Public Co Ltd (PTTEP):石油・ガス:M&Aディール及び事業提携情報
    Summary PTT Exploration and Production Public Company Limited (PTTEP), a subsidiary of PTT Public Company Limited, is an oil and gas company. It carries out exploration, development and production of hydrocarbons. The company manages an array of exploration projects in different stages and producing …
  • Dell Inc.:企業の戦略・SWOT・財務情報
    Dell Inc. - Strategy, SWOT and Corporate Finance Report Summary Dell Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • United Technologies Corp (UTX)-エネルギー分野:企業M&A・提携分析
    Summary United Technologies Corp (UTC) is a provider of high-technology products and services to the aerospace and building systems industries. The company’s building systems product portfolio includes elevators and escalators, moving walkways, heating, ventilating, air conditioning (HVAC) and refri …
  • Bandwidth Inc (BAND):企業の財務・戦略的SWOT分析
    Bandwidth Inc (BAND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mersana Therapeutics Inc (MRSN)-製薬・医療分野:企業M&A・提携分析
    Summary Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp, is a biotechnology company that develops immunoconjugate therapies to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes its Fleximer an …
  • Mitsubishi Electric Corp (6503):企業の財務・戦略的SWOT分析
    Mitsubishi Electric Corp (6503) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Takara Bio Inc (4974):企業の財務・戦略的SWOT分析
    Summary Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It of …
  • Allied Irish Banks, Plc:企業のM&A・事業提携・投資動向
    Allied Irish Banks, Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allied Irish Banks, Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆